ArticleACS applied bio materials2025
Minimalistic Peptide Nanocarriers for Multiple Cancer Drugs.
Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Amyloid-β "Co-assembles" with Coatomer Subunit Delta (δ-COP).The journal of physical chemistry letters · 2026Article
- Cyclo-(His-Phe) Complexes with Copper and Zinc Nanoparticles Have Antimicrobial Properties and Targeted Anticancer Potential Against Osteosarcoma Cells.Biomolecules · 2026Article
- Cell-Free DNA-Based Theranostics for Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The co-assembly of minimalistic peptides with cancer drugs, leading to the formation of nanocarriers for drug delivery, comprises a promising direction in chemotherapeutics. We computationally designed fluorescent minimalistic four-residue peptide nanocarriers for multiple cancer drugs: Epirubicin, Doxorubicin, Methotrexate, Mitomycin-C, 5-Fluorouracil, Camptothecin, and Cyclophosphamide. The optimally designed resulting nanocarriers formed by FFWH have notable drug encapsulation properties for the drugs investigated, according to both computational and experimental studies. Additionally, the nanocarriers possess biocompatibility, enhanced fluorescence, and uptake into HeLa cells using live cell confocal microscopic images. Our simulations demonstrate how the same peptide can efficiently be used to encapsulate these drugs as well as provide structural and biophysical understanding of their properties. We suggest that the designed nanocarriers can serve as programmable nanostructures for the future design of new generations of advanced nanocarriers with potential cancer- and patient-specific targeting properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.